This is exciting the market, Transgene has risen substantially:...

This is exciting the market, Transgene has risen substantially:

http://www.euronext.com/trader/summarizedmarket/stocks-2593-FR-FR0005175080.html;jsessionid=1F550331331250085E2953277FAE9EEB.7C3A5C3D6921002A783B492A3865022D?selectedMep=1&idInstrument=16329

Efficacy results below, note the improved survival times.

"The efficacy and safety of TG4010 have been assessed in a randomized, controlled Phase IIb study evaluating the therapeutic vaccine TG4010 as an adjunct to standard chemotherapy in 148 patients with advanced NSCLC. The primary objective of the study was met (Progression free survival at 6 months of at least 40% in the experimental arm). For the latest clinical trial data see the press releases on TG4010.



During the phase IIb trial, Transgene identified a subpopulation of patients who particularly benefited from the treatment with TG4010 and chemotherapy, versus chemotherapy alone. This sub-population consisted of patients with normal levels of activated NK cells (natural killer cells) at baseline and represented some 73 per cent of the evaluable patient population (101 out of 138 patients). The phase IIb clinical results have demonstrated an improved clinical outcome for patients in this subpopulation with a statistically significant 6 month increase in median survival (17.1 months in the experimental arm versus 11.3 months in the control arm). Response rate, time to progression and progression free survival data also confirmed the identification of activated NK cells as an appropriate predictive biomarker associated with the positive clinical outcome for patients with NSCLC treated with TG4010 in combination with chemotherapy.
"

... and lastly an analyst report on DNDN

http://www.scribd.com/doc/26195173/dndn-cowen